Cargando…
Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy
COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccin...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457318/ https://www.ncbi.nlm.nih.gov/pubmed/36078913 http://dx.doi.org/10.3390/jcm11174984 |
_version_ | 1784786025717956608 |
---|---|
author | Glowinska, Irena Labij-Reduta, Barbara Juzwiuk, Jerzy Lukaszewicz, Magdalena Pietruczuk, Adam Poplawska, Agata Daniluk-Jamro, Anna Kakareko, Katarzyna Rydzewska-Rosolowska, Alicja Naumnik, Beata Koc-Zorawska, Ewa Zorawski, Marcin Hryszko, Tomasz |
author_facet | Glowinska, Irena Labij-Reduta, Barbara Juzwiuk, Jerzy Lukaszewicz, Magdalena Pietruczuk, Adam Poplawska, Agata Daniluk-Jamro, Anna Kakareko, Katarzyna Rydzewska-Rosolowska, Alicja Naumnik, Beata Koc-Zorawska, Ewa Zorawski, Marcin Hryszko, Tomasz |
author_sort | Glowinska, Irena |
collection | PubMed |
description | COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccination. We performed a prospective longitudinal cohort study to determine longevity of the humoral response after SARS-CoV-2 vaccine. The study included 191 adult patients on hemodialysis and peritoneal dialysis. All participants had been vaccinated with three doses, either with BNT162b2 (Pfizer-BioNTech) (n = 109) or mRNA-1273 (Moderna) (n = 82). Anti-spike protein receptor-binding domain antibodies (anti-S IgG) were assessed using SARS-CoV-2 (RBD) IgG ELISA EIA-6150 IVD assay at baseline, on the 21st day and 43rd day, before a booster dose and two weeks thereafter. We found that before vaccination, 37.7% of the cohort had anti-S IgG titres concordant with seroconversion. After two-dose vaccination, seroconversion occurred in 97% of patients. The booster dose evoked a ~12-fold increase in antibody level. Obesity increased more than two-fold the odds for a decrease in anti-S IgG. Previous COVID-19 infection enhanced longevity of the humoral response following vaccination. In patients with previous COVID-19 infection, the BNT162b2 vaccine was associated with a higher odds of anti-S IgG waning compared to the mRNA-1273 vaccine. In conclusion, we report that obesity predisposes patients to protective antibody waning, hybrid immunity enhances odds for higher anti-S IgG concentrations and vaccine efficacy may be influenced by previous SARS-CoV-2 infection. The results might provide a rationale for vaccination protocol design. |
format | Online Article Text |
id | pubmed-9457318 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94573182022-09-09 Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy Glowinska, Irena Labij-Reduta, Barbara Juzwiuk, Jerzy Lukaszewicz, Magdalena Pietruczuk, Adam Poplawska, Agata Daniluk-Jamro, Anna Kakareko, Katarzyna Rydzewska-Rosolowska, Alicja Naumnik, Beata Koc-Zorawska, Ewa Zorawski, Marcin Hryszko, Tomasz J Clin Med Article COVID-19 has severely affected the population of patients with end stage renal disease. Current data have proved a two-dose vaccination schedule against SARS-CoV-2 to be effective among dialyzed patients. There are limited data on the longevity and modulating factors of humoral response after vaccination. We performed a prospective longitudinal cohort study to determine longevity of the humoral response after SARS-CoV-2 vaccine. The study included 191 adult patients on hemodialysis and peritoneal dialysis. All participants had been vaccinated with three doses, either with BNT162b2 (Pfizer-BioNTech) (n = 109) or mRNA-1273 (Moderna) (n = 82). Anti-spike protein receptor-binding domain antibodies (anti-S IgG) were assessed using SARS-CoV-2 (RBD) IgG ELISA EIA-6150 IVD assay at baseline, on the 21st day and 43rd day, before a booster dose and two weeks thereafter. We found that before vaccination, 37.7% of the cohort had anti-S IgG titres concordant with seroconversion. After two-dose vaccination, seroconversion occurred in 97% of patients. The booster dose evoked a ~12-fold increase in antibody level. Obesity increased more than two-fold the odds for a decrease in anti-S IgG. Previous COVID-19 infection enhanced longevity of the humoral response following vaccination. In patients with previous COVID-19 infection, the BNT162b2 vaccine was associated with a higher odds of anti-S IgG waning compared to the mRNA-1273 vaccine. In conclusion, we report that obesity predisposes patients to protective antibody waning, hybrid immunity enhances odds for higher anti-S IgG concentrations and vaccine efficacy may be influenced by previous SARS-CoV-2 infection. The results might provide a rationale for vaccination protocol design. MDPI 2022-08-25 /pmc/articles/PMC9457318/ /pubmed/36078913 http://dx.doi.org/10.3390/jcm11174984 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Glowinska, Irena Labij-Reduta, Barbara Juzwiuk, Jerzy Lukaszewicz, Magdalena Pietruczuk, Adam Poplawska, Agata Daniluk-Jamro, Anna Kakareko, Katarzyna Rydzewska-Rosolowska, Alicja Naumnik, Beata Koc-Zorawska, Ewa Zorawski, Marcin Hryszko, Tomasz Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy |
title | Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy |
title_full | Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy |
title_fullStr | Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy |
title_full_unstemmed | Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy |
title_short | Factors Influencing Longevity of Humoral Response to SARS-CoV-2 Vaccination in Patients with End Stage Kidney Disease Receiving Renal Replacement Therapy |
title_sort | factors influencing longevity of humoral response to sars-cov-2 vaccination in patients with end stage kidney disease receiving renal replacement therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457318/ https://www.ncbi.nlm.nih.gov/pubmed/36078913 http://dx.doi.org/10.3390/jcm11174984 |
work_keys_str_mv | AT glowinskairena factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT labijredutabarbara factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT juzwiukjerzy factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT lukaszewiczmagdalena factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT pietruczukadam factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT poplawskaagata factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT danilukjamroanna factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT kakarekokatarzyna factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT rydzewskarosolowskaalicja factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT naumnikbeata factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT koczorawskaewa factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT zorawskimarcin factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy AT hryszkotomasz factorsinfluencinglongevityofhumoralresponsetosarscov2vaccinationinpatientswithendstagekidneydiseasereceivingrenalreplacementtherapy |